Blood pressure destabilization on nonsteroidal antiinflammatory agents: Acetaminophen exposed?

Circulation

Volumn 122, Issue 18, 2010, Pages 1779-1781

  White, William B ^a   Campbell, Patrick ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

acetaminophen; ambulatory blood pressure monitoring; clinical trials; coronary artery disease; Editorials; hypertension; nonsteroidal antiinflammatory drugs

Indexed keywords

CANNABINOID RECEPTOR; CELECOXIB; CYCLOOXYGENASE 2; DICLOFENAC; ETORICOXIB; IBUPROFEN; INDOMETACIN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; ROFECOXIB;

BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BLOOD VOLUME; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EDEMA; EDITORIAL; HOMEOSTASIS; HUMAN; HYPERTENSION; OSTEOARTHRITIS; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTE ADHESION; VASCULAR RESISTANCE;

ACETAMINOPHEN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; HUMANS; HYPERTENSION; OSTEOARTHRITIS; PAIN; RISK FACTORS; VASODILATION;

EID: 78349308196     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.984054     Document Type: Editorial

References (27)

1. Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006: CD004257.pub2.doi:10.1002/14651858.
2. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007; 115:1634-1642.
3. White WB. Cardiovascular effects of the cyclooxygenase inhibitors. Hypertension. 2007;49:408-418.
4. Friedewald VE, Ram CV, Wesson DE, White WB, Williams GW, Roberts WC. Effect of nonsteroidal anti-inflammatory drugs on blood pressure: the editor's roundtable. Am J Cardiol. 2010;105:1759-1767.
5. Whelton A, Schulman G, Wallemark C, Drower EJ, Isakson PC, Verburg KM, Geis GS. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med. 2000;160:1465-1470.
6. White WB, Kent J, Taylor A, Verburg KM, Lefkowith JB, Whelton A. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension. 2002;39:929-934.
7. Izhar M, Alausa T, Folker A, Hunz GE, Bakris GL. Effects of COX-inhibition on blood pressure and kidney function in ACE-inhibitor treated blacks and Hispanics. Hypertension. 2004;43:574-577.
8. Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Igen H, Brabant T, Fort JG; Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis and type 2 diabetes. Arch Intern Med. 2005;165:161-168.
9. Campbell P, Ghuman N, Wakefield D, Wolfson L, White WB. Long-term reproducibility of ambulatory blood pressure is superior to office blood pressure in the very elderly [published online ahead of print March 4, 2010]. J Hum Hypertens. doi: 10.1038/jhh.2010.8.
10. Ghuman N, Campbell P, White WB. Role of ambulatory and home blood pressure recording in clinical practice. Curr Cardiol Rep. 2009;11: 414-421.
11. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investi-gators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092-1102.
12. Bertagnoli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TJ, Hoffmann N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET; APC Trial Inves-tigators. Celecoxib for the prevention of colorectal adenomas. N Engl J Med. 2006;355:873-884.
13. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B; PreSAP Trial investi-gators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355:885-895.
14. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352: 1081-1091.
15. Sudano I, Flammer AJ, Périat D, Enseleit F, Hermann M, Wolfrum M, Hirt A, Kaiser P, Hurlimann D, Neidhart M, Gay S, Holzmeister J, Nussberger J, Mocharla P, Landmesser U, Haile SR, Corti R, Vanhoutte PM, Lüscher TF, Noll G, Ruschitzka F. Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation. 2010;122: 1789-1796.
16. Aronoff DM, Oates JA, Boutaud O. New insights into the mechanism of action of acetaminophen: its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases. Clin Pharmacol Ther. 2006;79:9-19.
17. Ottani A, Leone S, Sandrini M, Ferrari A, Bertolini A. The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors. Eur J Pharmacol. 2006;531:280-281.
18. Kelley BG, Thayer SA. Anandamide transport inhibitor AM404 and structurally related compounds inhibit synaptic transmission between rat hippocampal neurons in culture independent of cannabinoid CB1 receptors. Eur J Pharmacol. 2004;496:33-39.
19. Wheat AJ, Bennett T, Randall MD, Gardiner SM. Cardiovascular effects of cannabinoids in conscious spontaneously hypertensive rats. Br J Pharmacol. 2007;152:717-724.
20. Bjorkman R. Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol: experimental studies in the rat Acta Anaesthesiol Scand Suppl. 1995;103:1-44.
21. 2 synthase nitration and suppresses eicosanoid production. Am J Pathol. 2006;168:349-362.
22. Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, Reisch JS, Schiodt FV, Ostapowicz G, Obaid Shakil A, Lee WM; Acute Liver Failure Study Group. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005;42:1364-1372.
23. Schnitzer TJ. Update on guidelines for the treatment of chronic muscu-loskeltal pain. Clin Rheumatol. 2006;25(suppl 1):S22-S29.
24. MacDonald TM, Reginster JY, Littlejohn TW, Richard D, Lheritier K, Krammer G, Rebuli R. Effects on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomizedtrial. J Hypertens. 2008;26:1695-1704.
25. Morgan TO, Anderson A, Bertram D. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens. 2000;13:1161-1167.
26. Polonia J, Boaventura I, Gama G, Camoes I, Bernardo F, Andrade P, Nunes JP, Brandao F, Cerqueira-Gomes M. Influence of non-steroidal anti-inflammatory drugs on renal function and 24h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal ther-apeutic system in hypertensive patients. J Hypertens. 1995;13:925-931.
27. Schwartz J, Thach C, Lasseter KC, Miller J, Hreniuk D, Hilliard DA, Snyder KM, Gertz BJ, Gottesdiener KM. Effects of etoricoxib and com-parator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure and other renal function indicators in elderly subjects consuming a controlled sodium diet. J Clin Pharmacol. 2007;47:1521-1531.